| 16th week of 2014 patent applcation highlights part 41 |
| Patent application number | Title | Published |
|---|
| 20140105812 | PROCESS FOR PREPARING CHROMIUM(III) OXIDE - Process for preparing chromium(III) oxide, which comprises the steps: | 2014-04-17 |
| 20140105813 | HYDROGEN RECYCLER WITH OXYGEN REACTOR - A hydrogen recycling system for a controlled atmosphere unit operation with an exhaust vent and an inlet port includes: a hydrogen recycle unit in fluid communication with the exhaust vent and in fluid communication with the inlet port; and an oxygen reactor being located between the controlled atmosphere unit operation and said hydrogen recycle unit and in fluid communication with the controlled atmosphere unit operation and said hydrogen recycle unit. | 2014-04-17 |
| 20140105814 | METHOD FOR HYDROGEN PRODUCTION - The present invention relates to a method for hydrogen production and to a method of hydrogen and/or carbon dioxide production from syngas. The method comprises the steps of: (i) providing a gas stream comprising hydrogen and carbon monoxide, (ii) separating at least part of hydrogen from the stream yielding a hydrogen-depleted stream, (iii) subjecting the hydrogen-depleted stream to a water-gas shift reaction, and (iv) separating hydrogen from the stream resulting from step (iii). The method according to the invention improves the conversion of carbon monoxide in the water gas shift reaction and allows to increase the hydrogen production by 10-15% and to increase the overall energy efficiency of the system by 5-7%. The invention further relates to a plant for hydrogen and/or carbon dioxide production suitable for the method of the invention. | 2014-04-17 |
| 20140105815 | HYDROGEN GAS PRODUCTION SYSTEM UTILIZING SILICON WASTEWATER AND METHOD FOR PRODUCTION OF HYDROGEN ENERGY USING THE SAME - Disclosed is a method for production of hydrogen energy utilizing silicon wastewater. The method includes treating the silicon wastewater through UF membrane filtration to separate UF treated water and a concentrated silicon waste solution therefrom, admixing the separated silicon waste solution with an alkaline material, reacting the concentrated silicon waste solution with the alkaline material in the mixture to produce hydrogen gas and alkaline water, using an acidic material to neutralize the alkaline water, thereby forming a supernatant and a precipitate. | 2014-04-17 |
| 20140105816 | AUTOTHERMAL AMMONIA CRACKER - Apparatus and methods are provided for separately preheating gaseous ammonia and an oxygen-containing gas mixture, combusting them to form a hydrogen-containing gas mixture, and cooling the hydrogen-containing gas mixture in conjunction with the preheating of the next ammonia and the preheating of the next oxygen-containing gas mixture. Combustion may occur at combinations of pressure and temperature that permit rapid and non-catalyzed decomposition of the ammonia. | 2014-04-17 |
| 20140105817 | Composition and Delivery Vehicle for Active Agents and Methods Therefor - A vehicle composition in the form of a vesicular composition or a particular composition and, optionally, an active agent associated with the vesicle forming components or particles, and folate receptor alpha is used as a delivery system for the transport of components and/or active agents into the cerebrospinal fluid (CSF) and/or brain and/or central nervous system and/or spinal cord. The composition is used for treating of CSF or brain pertaining diseases, disorders or conditions, such as preventing or treating neurological or neurodegenerative diseases, disorders or conditions. | 2014-04-17 |
| 20140105818 | Novel Vesicles and Nanostructures from Recombinant Proteins - The present invention includes a composition comprising at least one oleosin-like protein. The present invention also includes a composition comprising a vesicle comprising at least one oleosin-like protein. | 2014-04-17 |
| 20140105819 | In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents - The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for | 2014-04-17 |
| 20140105820 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES - The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent. | 2014-04-17 |
| 20140105821 | ANTIBODY THAT STOPS OR SLOWS TUMOUR GROWTH (VARIANTS) - A monoclonal antibody is described herein specifically binding to domains II and IIIc of FGFR1 or to a complex of fibroblast growth factor receptor type 1 and heparan sulphate. A method is proposed for suppressing tumour growth, based on blocking the human fibroblast growth factor/human fibroblast growth factor receptor type 1 (domains II and IIIc) pathway and involves administering the antibody. A conjugate of the antibody and contrast agents is proposed intended for use in diagnosing malignant and other growths, whose cells express large quantities of FGFR1. A method is proposed for diagnosing malignant neoplasms. The proposed methods enable blocking the fibroblast growth factor/fibroblast growth factor receptor type 1 pathway by means of binding to domains II and IIIc of FGFR1, thus stopping or slowing tumour growth. The methods present novel preparations for the diagnosis and treatment of diseases related to overproliferation and neovascularization. | 2014-04-17 |
| 20140105822 | NANOSPHERES COMPRISING TOCOPHEROL, AN AMPHIPHILIC SPACER AND A THERAPEUTIC OR IMAGING AGENT - This invention relates to a nanosphere comprising tocopherol, an amphiphilic spacer and a therapeutic agent, an imaging agent, a hydrophobic antioxidant, a hydrophobic nonsteroidal anti-inflammatory drug (NSAID) derivative, a hydrophobic antioxidant and anti-inflammatory derivative of a nonsteroidal anti-inflammatory drug (NSAID), a statin lactone derivative, an antioxidant derivative of camptothecin or camptothecin analog, or a combination thereof. Methods of synthesizing the nanospheres and their use in treating, detecting or diagnosing diseases are also provided. | 2014-04-17 |
| 20140105823 | MOLECULES SPECIFICALLY BINDING PANCREATIC BETA CELLS BIOMARKERS - The present invention provides a synthetic peptide molecule that specifically binds an FXYD2-gamma isoform of pancreatic beta cells, said synthetic peptide molecule has 25 amino acids. | 2014-04-17 |
| 20140105824 | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods - Provided herein are diagnostic methods for identifying subjects susceptible to treatment with a hypoxia-activated agent, and related methods. Also provided herein are methods of monitoring treatments with anti-hyaluronan agents, and related methods. | 2014-04-17 |
| 20140105825 | Systems, Methods, and Apparatus for Imaging of Diffuse Media Featuring Cross-Modality Weighting of Fluorescent and Bioluminescent Sources - In certain embodiments, the invention relates to systems and methods for in vivo tomographic imaging of fluorescent probes and/or bioluminescent reporters, wherein a fluorescent probe and a bioluminescent reporter are spatially co-localized (e.g., located at distances equivalent to or smaller than the scattering mean free path of light) in a diffusive medium (e.g., biological tissue). Measurements obtained from bioluminescent and fluorescent modalities are combined per methods described herein. | 2014-04-17 |
| 20140105826 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 2014-04-17 |
| 20140105827 | METHOD OF SCREENING FOR COLON CANCER USING BIOMARKERS - The present invention relates to biomarkers for colon cancers, specifically adenomas and adenocarcinomas in the GI tract. The inventors have discovered that the expression and/or overexpression of biomarkers such as CLDN1, GPR56, GRM8, LY6G6D, TLR4 and SLCO1B3 are indicative of adenomas and adenocarcinomas. A method of detecting colon cancer using targeted molecular imaging agents is also presented. | 2014-04-17 |
| 20140105828 | NANOPARTICLES CARING NUCLEIC ACID CASSETTES FOR EXPRESSING RNA - This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents. | 2014-04-17 |
| 20140105829 | THERAPEUTIC NANOEMULSION FORMULATION FOR THE TARGETED DELIVERY OF DOCETAXEL AND METHODS OF MAKING AND USING THE SAME - A novel nanoemulsion formulation useful for the delivery of docetaxel chemotherapeutic agents is provided, as well as methods of their preparation and use in cancer patients and for cancer imaging. | 2014-04-17 |
| 20140105830 | ABUSE-PROOFED DOSAGE FORM - The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 2014-04-17 |
| 20140105831 | LIQUID DETERGENT COMPOSITION WITH ABRASIVE PARTICLES - A composition comprising abrasive particles derived from inorganic-based foam, wherein said abrasive particles are non-spherical having a form factor from 0.1 to 0.6 and a solidity from 0.3 to 0.9, and wherein said abrasive particles comprise one or more inorganic materials and have a MOHs hardness of from 1 to 4. | 2014-04-17 |
| 20140105832 | COMPOSITIONS AND METHODS FOR TEETH WHITENING - Disclosed herein are teeth whitening compositions generally including an oxidizing agent, and an activating agent that has an emission wavelength between about 400 nm and about 570 nm. Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described. | 2014-04-17 |
| 20140105833 | Process For Surfactant Taste And/Or Odor Improvement - Processes for improving the taste of water-soluble surfactants using liquid-liquid solvent extraction, said process comprising the steps of: providing a water-soluble surfactant composition in need of treatment wherein said water-soluble surfactant composition comprises a water-soluble surfactant and one or more undesirable non-polar materials; contacting said water-soluble surfactant composition with an extraction solvent and water to form an extraction mixture comprising an aqueous phase and a solvent phase; and separating the aqueous phase from the solvent phase; wherein the extraction solvent is selected from solvents having individual Hansen solubility parameters of a dispersion force component (δ | 2014-04-17 |
| 20140105834 | METHOD FOR NON-SURGICAL FACIAL REJUVENATION - A method for non-surgical rejuvenation of facial skin to correct both Type 1 aging changes in the epidermis layer of the skin causing visual changes in the skin and Type 2 aging changes in the dermis layer of the skin causing damage to supportive elements of the skin. The method includes the steps of exfoliation of the facial skin, stimulation of new dermal collagen deposition, removal of at least one of pigment and superficial blood vessels, relaxation of facial expression muscles, filling of soft tissue defects including at least one of deep facial lines and contour deformities, and tightening of the facial skin, and the steps of the method are applied according to a selected one of a plurality of age determined regimens. | 2014-04-17 |
| 20140105835 | SUNLESS TANNING COMPOSITION AND METHODS FOR USING - A sunless tanning composition is provided according to the invention. The sunless tanning composition includes an effective amount of a tanning active component to provide a darkening effect of skin tissue after exposure to the skin tissue, a polymer component, water, an effective amount of an acidifying agent to provide the composition with a pH of less than about 5, and wherein the composition has the viscosity of at least about 3,000 cSt. The polymer component can be characterized as a skin bonding polymer component to hold the tanning active component in exposure to the skin tissue when applied to the skin tissue. The polymer component can be characterized as a polymer having an average molecular weight of about 2,000 to about 500,000. A method of applying a sunless tanning composition to skin tissue is provided. | 2014-04-17 |
| 20140105836 | LIPSTICK AND OTHER COSMETICS AND METHOD OF MAKING - Inventive subject matter disclosed herein relates to a lipstick. The lipstick includes a colorant paste comprising one or more dry pigments and fractionated coconut oil; a coconut gel comprising vegetable oil, Cocos Nucifera Oil, a styrene/butadiene copolymer and polyethylene; and Polyethylene, caprylyl glycol, and a mixture of Acacia Decurrens/Jojoba/Sunflower Seed wax/Polyglyceryl 3-ester in concentrations effective for ensuring coconut gel and fractionated coconut oil are melted and homogeneous. | 2014-04-17 |
| 20140105837 | NOVEL ARYL C-XYLOSIDE COMPOUNDS, AND COSMETIC USE - The present invention relates to novel compounds of formula (I) | 2014-04-17 |
| 20140105838 | BLOCK POLYMER INCLUDING ISOBUTYL ACRYLATE AND ACRYLIC ACID, COSMETIC COMPOSITION AND TREATMENT METHOD - The present invention relates to a diblock or triblock polymer of AB, ABA or BAB structure, comprising at least one block A which comprises isobutyl acrylate and acrylic acid. The invention also relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one such polymer, and also to a treatment process using it. | 2014-04-17 |
| 20140105839 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS - The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin. | 2014-04-17 |
| 20140105840 | Solid Cosmetic For Lips - The present invention provides a solid cosmetic for lips that has excellent secondary adhesion resistance effect, excellent feeling in use, gloss durability, and excellent stability. The solid cosmetic for lips of the present invention is characterized by comprising the following (a) to (d):
| 2014-04-17 |
| 20140105841 | USE OF CHARGED SURFACTANTS FOR REDUCING TEXTILE STAINING BY ANTIPERSPIRANTS - Disclosed is cosmetic or dermatological preparation which comprises one or more antiperspirant substances and one or more cationic surfactants. | 2014-04-17 |
| 20140105842 | COMPOSITION AND METHOD OF DELIVERY - An anhydrous composition comprising a base and a metal organic framework formed from a recyclable porous material with the material adsorbed into the metal organic framework, wherein the recyclable porous material has a structure that breaks down when contacted with water to release the material. | 2014-04-17 |
| 20140105843 | PROCESS AND DEVICE FOR THE PREPARATION OF AN ESTER IN GRANULE FORM - The present invention relates to a process for the preparation of an ester comprising an after-treatment of the ester to give an ester in granule form of defined particle size distribution, a device for carrying out this process, a process for the preparation of a thermoplastic composition comprising the ester prepared according to the invention, a process for the production of a shaped article comprising the ester according to the invention or the thermoplastic composition according to the invention, a process for the production of a packed product, a process for the production of an at least partly coated object, and uses of the esters according to the invention as an additive in various compositions. | 2014-04-17 |
| 20140105844 | HUMAN SEBUM MIMETICS DERIVED FROM BOTANICAL SOURCES AND METHODS FOR MAKING THE SAME - Human sebum mimetics and methods for producing human sebum mimetics are provided. In one exemplary embodiment, a human sebum mimetic comprises a wax ester derived from interesterification of a refined botanical triglyceride oil comprising palmitoleic acid and refined jojoba oil, a phytosterol, phytosqualene, and phytosteryl macadamiate. A method for producing a human sebum mimetic comprises mixing refined macadamia oil and refined jojoba oil, interesterifying the macadamia oil and the jojoba oil, adding a phytosterol, adding phytosteryl macadamiate, and adding phytosqualene after interesterification. | 2014-04-17 |
| 20140105845 | COSMETIC COMPOSITIONS COMPRISING WAX DISPERSIONS - The disclosure relates to compositions comprising at least one film former and at least one wax dispersion. The disclosure further relates to methods of improving the ease of removability of compositions. | 2014-04-17 |
| 20140105846 | COSMETIC POLYURETHANEUREA COPOLYMER COMPOSITION - The present invention relates to a cosmetic polyurethaneurea copolymer composition comprising a solvent, a polyurethaneurea and a copolymer, said polyurethaneurea being obtainable by reacting a single polyisocyanate component containing at least 75 mol % of IPDI, at least one polymeric polyol component, at least one hydrophilizing component and a single diamine component containing at least 75 mol % of IPDA, and said copolymer being obtainable by reaction of at least one monomer including acrylate groups with at least one further monomer. The invention further provides for the use of the cosmetic composition in cosmetics and a method for shaping hairstyles using the cosmetic composition. | 2014-04-17 |
| 20140105847 | STRUCTURED DEPILATORY COMPOSITIONS - Provided are compositions comprising a depilatory active; and a surfactant, wherein the composition has a Yield Stress of from about 1 Pascal (Pa) to about 1500 Pa, and methods of use thereof. | 2014-04-17 |
| 20140105848 | POTASSIUM BINDING POLYMERS FOR TREATING HYPERTENSION AND HYPERKALEMIA - The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding polymer to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function. | 2014-04-17 |
| 20140105849 | BIOACTIVE ANILINE COPOLYMERS - Aniline copolymers and the synthesis thereof for use as antimicrobial (antibacterial, antifungal or antiviral material) material for the manufacture of antimicrobial objects, suitable for use in the health, food, packaging, water, paint, wood, textile, poultry, glass, paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. The copolymer may be for example (A): where for example R | 2014-04-17 |
| 20140105850 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 2014-04-17 |
| 20140105851 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and/or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H | 2014-04-17 |
| 20140105852 | CROSS-LINKED POLYSACCHARIDE COMPOSITION - A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications. | 2014-04-17 |
| 20140105853 | PROSTATE CANCER VACCINE - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. | 2014-04-17 |
| 20140105854 | VACCINE FOR TREATMENT AND PREVENTION OF HERPES SIMPLEX VIRUS INFECTION - The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided. | 2014-04-17 |
| 20140105855 | STRUCTURAL BASED DESIGN OF IL-17 DOMINANT NEGATIVE MUTANTS - IL-17 Receptor binding proteins, including non-naturally occurring and recombinantly modified proteins, methods of making and using such molecules as therapeutic, prophylactic and diagnostic agents are provided. | 2014-04-17 |
| 20140105856 | System and Method for Collagen Isolation - System and methods for isolation of collagen and other fibrous tissue from adipose tissue are described herein. The method of the present invention isolates the collagen from adipose tissue by sonication. The tissue to be sonicated is placed in a container or a flow cell transparent to ultrasound waves. After sonication the sonicated material is filtered out through the bottom of the flow cell and the sonicated collagen is trapped in the filter, which may be taken for further processing. The isolated collagen can then be combined with a suitable carrier for re-injection to correct various tissue defects such as wrinkles, to form a carrier for the stem cells, a filler, and matrix for new collagen production by injecting into the desired area of the host. | 2014-04-17 |
| 20140105857 | COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION - Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided. | 2014-04-17 |
| 20140105858 | IFN-BETA COMPOSITIONS, PREPARATION METHODS AND USES THEREOF - The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26,000 and 40,000 g/mol, grafted with alpha-tocopherol substituents, the average molar grafting ratio being 4.5-5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time. | 2014-04-17 |
| 20140105859 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula I, | 2014-04-17 |
| 20140105860 | ENGINEERED ANTIBODY-TNFSF MEMBER LIGAND FUSION MOLECULES - The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities, thus improving the therapeutic index of the engineered fusion molecules. | 2014-04-17 |
| 20140105861 | COMPOSITIONS AND METHODS FOR TREATING ENDOCRINE, GASTROINTESTINAL OR AUTOIMMUNE DISORDERS - Recombinant cells and methods are provided that relate to the use of isolated, engineered recombinant cells to directly or indirectly treat diseases or disorders in a mammalian host such as endocrine, gastrointestinal or autoimmune disorders. A recombinant cell is provided that comprises a signal sequence and a promoter, wherein: the signal sequence is capable of regulating signal-dependent expression of a target nucleic acid in a host or is capable of regulating signal-dependent expression of a target nucleic acid in response to an environmental stimulus, the cell is derived from an enteric or a commensal bacterium, and the target nucleic acid encodes a mammalian factor that promotes normal functioning of a physiological process in the host or is effective in preventing onset, establishment, or spread of a non-infectious disease in the host. The recombinant cell is administered to the host to treat the disease or disorder. | 2014-04-17 |
| 20140105862 | STREPTOMYCES MICROFLAVUS STRAINS AND METHODS OF THEIR USE TO CONTROL PLANT DISEASES AND PESTS - The present invention relates to novel strains of | 2014-04-17 |
| 20140105863 | POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA - The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium. | 2014-04-17 |
| 20140105864 | COMPOSITIONS COMPRISING PHYTOESTROGENS SELECTIVE FOR ESTROGEN BETA RECEPTOR AND DIETARY FIBRES - Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-β, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia. | 2014-04-17 |
| 20140105865 | PREVENTING DISEASES IN INFANTS DELIVERED VIA CAESAREAN SECTION - The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. | 2014-04-17 |
| 20140105866 | BACTERIOPHAGES USEFUL FOR THE PROPHYLAXIS AND THERAPY OF VIBRIO ANGUILLARUM - An isolated strain of bacteriophage, specific against bacteria belonging to the | 2014-04-17 |
| 20140105867 | BLOCKAGE OF PAI-1 IN DIABETIC CD34+ STEM CELLS CORRECTS CELLULAR DYSFUNCTION - Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which PAI-1 expression and/or activity has been transiently blocked. Other methods involve the administration of a PAI-1 blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a PAI-1 blocking agent and treated cells are co-administered to a subject in need thereof. | 2014-04-17 |
| 20140105868 | METHOD FOR TREATING VASCULAR-RELATED DISEASE - A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis. | 2014-04-17 |
| 20140105869 | Compositions and Methods for Treating Musculoskeletal Diseases and Disorders - Compositions and methods for modulating miRNAs up-regulated or down-regulated in aged individuals and their downstream targets are disclosed. Methods of treating musculoskeletal disorders are also provided. | 2014-04-17 |
| 20140105870 | Differentiation of Human IPS Cells to Human Alveolar Type II Via Definitive Endoderm - The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell. | 2014-04-17 |
| 20140105871 | Use Of Mesenchymal Stem Cells For The Improvement Of Affective And Cognitive Function - Disclosed is the use of mesenchymal stem cells (MSCs) and in particular MSCs pretreated with pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs and fragments of PACAP, for treatment of neurodegenerative and psychiatric diseases, and for the improvement of affective and cognitive function in a normal individual or in an individual suffering from a neurodegenerative or neuropsychiatric disease. | 2014-04-17 |
| 20140105872 | PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF PURIFYING MESENCHYMAL STEM CELL COMPOSITIONS - One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed. | 2014-04-17 |
| 20140105873 | AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY - The invention teaches antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Further elaborated are methods, uses and further products employing such agents. | 2014-04-17 |
| 20140105874 | BACTERIAL STRAINS CAPABLE OF METABOLIZING OXALATES - A selection of strains of lactic bacteria and bifidobacteria of human intestinal origin capable of metabolizing oxalates is described. Moreover, a food composition or supplement product or pharmaceutical composition containing said bacterial strains is also described. | 2014-04-17 |
| 20140105875 | NUTRITIONAL COMPOSITIONS HAVING EXOGENOUS MILK FAT GLOBULE MEMBRANE COMPONENTS - Nutritional compositions including milk fat globule membrane components (“MFGM”) and at least one nutrient are provided. The milk-derived, bioactive lipids help to modulate conditions typically found in the elderly including, for example, low-grade inflammation, loss of lean body mass, skeletal muscle cell membrane instability, and joint inflammation. The nutrients may include, but are not limited to, whey protein micelles, citrulline, branched chain fatty acids, and a-hydroxycaproic acid (“α-HICA”). Methods for treating an individual having, or at risk of having, a medical condition are also provided. | 2014-04-17 |
| 20140105876 | CERAMIC BIOCOMPOSITE FOR BONE REGENERATION - The invention relates to a ceramic biocomposite for bone regeneration, having a pH range of between 6.5 and 8.5, with an initial plasticity that allows the biocomposite to be easily moulded in situ and to set after 7 minutes, meaning that it can remain at the indicated location during the healing process. In addition, the biocomposite has demonstrated an ability to stimulate bone formation in hard-to-heal wounds. The material can act alone or in combination with other types of bone graft such as autografts, homografts or xenografts which act as a vehicle, as a binding material for endosseous prostheses or as a covering for endosseous implants or prostheses. | 2014-04-17 |
| 20140105877 | COMPOSITION FOR MODERATING ALCOHOL METABOLISM AND FOR REDUCING THE RISK OF ALCOHOL INDUCED DISEASES - The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases. In this respect, the present invention is also directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively, which supports and/or moderates the alcohol degradation process within the human body. | 2014-04-17 |
| 20140105878 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF MIGRAINES - A therapeutic composition for preventing migraines is described. The therapeutic composition may include riboflavin, magnesium, feverfew and coenzyme Q10. | 2014-04-17 |
| 20140105879 | FLOUR-BASED FUNCTIONAL FOOD - The invention relates to a functional flour-based food composition, in particular baked products, and a method for the preparation thereof. Specific substances of vegetable origin principally containing policosanols, isoflavones and vegetable statins are added to the flour, or to the dough for preparing the aforesaid baked products. Further components can be added to the preparation in order to enhance the effectiveness and sensory qualities thereof. The functional food composition of the invention favours the re-balancing of cholesterol and triglyceride values. | 2014-04-17 |
| 20140105880 | USE OF P97 AS AN ENZYME DELIVERY SYSTEM FOR THE DELIVERY OF THERAPEUTIC LYSOSOMAL ENZYMES - The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain harrier. | 2014-04-17 |
| 20140105882 | THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 2014-04-17 |
| 20140105883 | Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds - Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases. | 2014-04-17 |
| 20140105884 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES - Disclosed herein are materials, means and methods for sustained release of therapeutic agents for topical treatments. In particular, disclosed are means and methods for topical treatment of diseases of internal body cavities by embedding therapeutic agents in a slowly degrading biocompatible mixture applied to affected tissue. | 2014-04-17 |
| 20140105885 | Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens - Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided. | 2014-04-17 |
| 20140105886 | ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME - Glioblastoma multiforme (GBM) is an aggressive form of brain cancer. Biomarkers for GBM that provide prognostic and predictive information are useful because they provide the physician valuable information regarding treatment options for GBM. The present invention provides a method to quantify such biomarkers. Thus, the method relates to the quantification of GSK3β, S6, CREB, PTEN, AKT and mTOR biomarkers and the use of AQUA® analysis to estimate a patient's risk and benefit to treatment using an inhibitor of the AGC-family kinase. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. The present invention uses the AQUA system to provide a robust and standardized diagnostic assay that can be used in a clinical setting to provide prognostic and predictive information. | 2014-04-17 |
| 20140105887 | METHODS FOR MODULATING IL-33 ACTIVITY - Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling. | 2014-04-17 |
| 20140105888 | NOVEL MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided. | 2014-04-17 |
| 20140105889 | METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE - The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fcγ receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response. | 2014-04-17 |
| 20140105890 | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE - The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease. | 2014-04-17 |
| 20140105891 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 2014-04-17 |
| 20140105892 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations. | 2014-04-17 |
| 20140105893 | METHOD FOR SELECTING CHEMOTHERAPY FOR GASTRIC CANCER PATIENT USING COMBINATION DRUG OF TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM AND EGFR INHIBITOR - A method for predicting a therapeutic effect of chemotherapy with a combination drug containing tegafur, gimeracil, and oteracil potassium in a gastric cancer patient by:
| 2014-04-17 |
| 20140105894 | HUMANIZED ANTI-IL-18 ANTIBODIES - The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential. | 2014-04-17 |
| 20140105895 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent. | 2014-04-17 |
| 20140105896 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 2014-04-17 |
| 20140105897 | Novel Anti-IL13 Antibodies and Uses Thereof - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 2014-04-17 |
| 20140105898 | APOPTOSIS-INDUCING MOLECULES AND USES THEREFOR - This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists, including nucleic acids such as TRAIL polynucleotides, peptides and polypeptides including TRAIL polypeptides, TRAIL DR agonist antigen-binding molecules, TRAIL DR peptide agonists as well as small molecule TRAIL DR agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome. | 2014-04-17 |
| 20140105899 | ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME - The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes. | 2014-04-17 |
| 20140105900 | METHODS AND COMPOSITIONS RELATING TO ANTI-IL-21 RECEPTOR ANTIBODIES - The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor. | 2014-04-17 |
| 20140105901 | USE OF CBL AS BIOMARKER FOR IDENTIFYING SUBJECT SUITABLE FOR TREATMENT WITH ANTI-C-MET ANTIBODY - A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods. | 2014-04-17 |
| 20140105902 | USE OF LRIG1 AS A BIOMARKER FOR IDENTIFYING A SUBJECT FOR APPLICATION OF ANTI-C-MET ANTIBODIES - A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions. | 2014-04-17 |
| 20140105903 | Modulators of Plexin B2 Activity - Disclosed herein are novel compositions and methods for the inhibition of Plexin B2-mediated Angiogenin activity. Such compositions and methods are useful, for example, for the treatment of cancer, the treatment of wet AMD and the inhibition of angiogenesis. Also disclosed herein are methods of determining whether a test agent is a modulator of Plexin B2 activity. | 2014-04-17 |
| 20140105904 | ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USE - Isolated peptides of the | 2014-04-17 |
| 20140105905 | High Affinity Fully Human Monoclonal Antibodies To Interleukin-8 And Epitopes For Such Antibodies - The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. | 2014-04-17 |
| 20140105906 | Peptide for Protection of Allergic Respiratory Disorders - A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO). Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma. | 2014-04-17 |
| 20140105907 | ANTI-CD40 ANTIBODY MUTANTS - A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2. | 2014-04-17 |
| 20140105908 | METHODS FOR TREATING PROSTATE CANCER - Disclosed herein are methods and compositions for reducing the recurrence of prostate cancer and for treating prostate cancer. | 2014-04-17 |
| 20140105909 | SCLEROSTIN ANTIBODY CRYSTALS AND FORMULATIONS THEREOF - Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals. | 2014-04-17 |
| 20140105910 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and typically neutralize | 2014-04-17 |
| 20140105911 | Method Of Treatment Of Vascular Complications - The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and/or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and/or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of TXNIP and/or an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of TRX is/are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and/or activity and/or level and/or TRX expression and/or activity and/or level for use in such therapeutic and prophylactic methods. | 2014-04-17 |
| 20140105912 | VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER - The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1). | 2014-04-17 |
